NUI Maynooth spinout Avectas has added capital to converted equity previously supplied by therapeutics developer Adapt Pharma among others.

Avectas, an Ireland-based cell engineering platform developer spun out of National University of Ireland (NUI) Maynooth, has closed a $10m round led by private investor Seamus Mulligan that involved a group of unnamed biotech-focused backers. Founded in 2012 as Profector Life Sciences, Avectas has built a cell engineering platform called Solupore that enables drug developers…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.